We can’t show the full text here under this license. Use the link below to read it at the source.
Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes
Treatment satisfaction and blood sugar control after 16 weeks of iGlarLixi in adults new to insulin with poorly controlled type 2 diabetes
AI simplified
Abstract
(TIR) increased from 26.4% at baseline to 52.7% at Week 16 with iGlarLixi treatment.
- Treatment satisfaction, measured using the (DM-SAT), showed a mean overall score increase from 0.59 at baseline to 0.78 at Week 16.
- A total of 118 (95.9%) participants completed the DM-SAT at baseline, and 107 (87.0%) at Week 16.
- Trends in improvement were observed across all four domains of treatment satisfaction: well-being, medical control, lifestyle, and convenience.
- The improvement in TIR was positively associated with improvement in overall treatment satisfaction, though the correlation was weak (mean r = 0.14).
AI simplified
Key numbers
0.18
Increase in Overall Treatment Satisfaction Score
Mean score increased from 0.59 at baseline to 0.78 at Week 16.
26.4% to 52.7%
Increase in ()
improved significantly from baseline to Week 16.
107 of 123
Participant Completion Rate
Number of participants who completed the at Week 16.